ALK genomic tumor aberrations negative
2 drugsPredictive biomarker for patient selection in 7 indications
2
Approved Drugs
7
Indications
2
Companies
ALK genomic tumor aberrations negative is a precision-medicine biomarker linked to 2 FDA-approved targeted drugs from 2 companies, spanning 7 indications including Non-Small Cell Lung Cancer, Malignant Pleural Mesothelioma, Small Cell Lung Cancer. Explore the targeted therapies, indications, testing methods, and companies developing ALK genomic tumor aberrations negative drugs below.
Search ALK genomic tumor aberrations negative Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting ALK genomic tumor aberrations negative
| Drug | Company | Therapeutic Area |
|---|---|---|
| AXTLE | AVYXA HOLDINGS | Oncology |
| TECENTRIQ HYBREZA | Roche | Oncology |
ALK genomic tumor aberrations negative Indications
Non-Small Cell Lung Cancer Malignant Pleural Mesothelioma Small Cell Lung Cancer Hepatocellular Carcinoma Melanoma Alveolar Soft Part Sarcoma Muscle Invasive Bladder Cancer